Data quality of drug-resistant tuberculosis and antiretroviral therapy electronic registers in South Africa

CURRENT STATUS: ACCEPTED

Lise Jamieson
Health Economics and Epidemiology Research Office

Corresponding Author
ORCiD: https://orcid.org/0000-0003-2354-4580

Denise Evans
University of the Witwatersrand Faculty of Health Sciences

Rebecca Berhanu
University of the Witwatersrand Faculty of Health Sciences

Nazir Ismail
National Institute for Communicable Diseases

Samantha Aucock
Tuberculosis and HIV Investigative Network

Kristina Wallengren
Tuberculosis and HIV Investigative Network

Lawrence Long
Boston University

DOI:
10.21203/rs.2.14403/v1

SUBJECT AREAS
Health Economics & Outcomes Research Health Policy

KEYWORDS
EDR-Web, Tier.net, data quality
Abstract
Background To assess the quality and completeness of treatment and outcome data in the electronic tuberculosis (TB) and antiretroviral treatment (ART) registers in drug-resistant (DR-) TB patients at three treatment facilities in South Africa.

Methods We did a retrospective cohort study using routinely-collected data from DR-TB registers of rifampicin resistant adults (≥18 years old), on ART, initiating DR-TB treatment between January 2012 and December 2013. We linked patient information from the DR-TB register to the ART register using patient identifiers and an algorithm based on string edit distance and date of birth. We describe data gaps and discrepancies found.

Results Overall, 2,852 DR-TB patients met our inclusion criteria based on the DR-TB register data, and of these, 1,685 (59%) could be matched to the ART registers. An additional 253 patients from the DR-TB registers were found in the ART registers, having initiated ART, despite the DR-TB register indicating that they were not on ART (or this data was missing). 11% of matched patients did not have TB treatment status recorded in the ART register despite being recorded as being on TB treatment in the DR-TB register, and 78% did not have an ART start date recorded in DR-TB register despite being on ART treatment as per the ART register. 11% of matched patients had a death recorded in one register but not the other, and of those with death recorded in both, 15% of dates differed by >1 month.

Conclusions The underreporting of death and the lack of ART or TB status in the electronic DR-TB and ART registers could negatively impact monitoring efforts by downplaying the state of the TB/HIV epidemic. Improved recording of these data sources, and data integration across systems, could improve the accuracy of reporting for the national HIV/ART and TB programs.

Background
South Africa has the largest population of patients on antiretroviral therapy (ART) at 4.36 million (1). Approximately 322,000 active tuberculosis (TB) cases and 16,000 new multi-drug resistant (MDR) or rifampicin-resistant (RR-) TB cases are estimated to occur each year (2). The majority of the population affected by HIV and TB access their treatment through the public healthcare system. While
health facilities keep their own paper records and registers, they are required to report into the national electronic registers for monitoring of HIV and TB. Two TB registers are widely in use: the national electronic TB register (ETR) data for drug-sensitive TB and the electronic drug-resistant TB register (EDRWeb) for drug-resistant (DR)-TB. The Integrated Electronic Registers (Tier.Net) is a national monitoring/evaluation software system used to capture standardized data of patients on ART (3). Introduced in 2011, it is used in over 3,000 facilities in South Africa.

Effective monitoring of the national HIV and TB programmes relies on complete, accurate data. Knowing drug-resistant TB incidence within the HIV programme is critical. Furthermore, HIV infection rates and ART uptake amongst patients with TB are key indicators of TB and HIV programme integration. Accurate recording and reporting is crucial for programme monitoring, resource allocation, policy making and epidemiological analysis.

To date, no study has assessed the quality and completeness of Tier.Net while a few studies in South Africa have assessed the quality and completeness of the ETR and EDRWeb (4–7). A study of pediatric TB cases demonstrated that a third of these are never recorded in the ETR (4), and another study found that in EDRWeb, 12% have missing HIV status and 4% have incorrect HIV status (7). Although 90% of adult patients with TB are recorded in the ETR (6), estimates for accurate reporting of HIV status range between 53.9% and 79% (5, 6) and reporting of ART status is as low as 24% (6). In a study comparing ETR to clinic source documents, agreement of ART status and TB treatment outcome was low at 59% and 47%, respectively (5). A study comparing ETR data to the National Health Laboratory Service data found 20% of smear positive TB cases were not registered in the ETR and only 69.9% had patient records at the facilities from where the sample was sent (8).

We linked routinely-collected data from DR-TB and ART registers using patient identifiers (name, surname, date of birth, national identification number, if available). This paper aims to describe the methods used to match patients across routine data platforms, and data gaps and discrepancies found.

Methods
Data sources
In 2016/17 we extracted EDRWeb and Tier.Net data for two South African healthcare facilities. In addition to EDRWeb and Tier.Net, we included two additional sources of TB and HIV data, as these systems were used at a third healthcare facility we evaluated: the Focal Point Information System (FIS) is an electronic TB patient record system, allowing for multi-point data entry and is being used at three DR-TB treatment sites in South Africa. TherapyEdge-HIV™ (TE) is an electronic medical database system designed for HIV patient management currently used at six sites in South Africa. FIS and TE are more comprehensive than EDRWeb and Tier.Net in terms of variables collected.

Study sites
The three facilities were based in the Gauteng and KwaZulu-Natal provinces. One is an outpatient Non-Governmental Organization (NGO)-supported DR-TB clinic at a public academic hospital. Another facility is a MDR-TB hospital providing inpatient and outpatient care. The third facility is an outpatient DR-TB centre. To maintain anonymity, we labelled them Site 1, 2 and 3. Site 1 uses the FIS and TE systems, while sites 2 and 3 use EDRWeb and Tier.Net.

Inclusion criteria for the study were: adults (aged 18+ years), laboratory diagnosis of rifampicin (RIF) resistant TB, initiated second-line TB treatment between January 2012-December 2013, and HIV positive on ART. Since the DR-TB registers may have incomplete HIV status and/or ART initiation information, we also matched DR-TB patients with negative/missing HIV status, or HIV positive and not on ART (or whose ART status was unknown/missing) in the DR-TB register, to the ART register, in order to confirm HIV and/or ART status.

Matching algorithm
We matched patients from the DR-TB register to their ART record by first merging those where the first letter of either the name or surname matched, and then using a generalized Levenshtein edit distance (9) to match names and surnames between the two datasets. The edit distance is a measure of similarity between two strings. Second or third names were also considered, if recorded. SAS version 9.3 was used for analysis, and the built-in function, COMPGED (10) was used.

Patients were marked as a match if their name in the one dataset matched their name in the other dataset with an edit distance of 100 or less (11, 12), and their birthdate matched. For patients with a
missing date of birth, we matched on patient age and gender, alongside the names, allowing for a 1-year difference. For a birthdate match, we allowed for the year to shift up or down by one year, and we allowed for the month of birth to shift up or down by one month. We also allowed for the birthdate day and month to be erroneously switched in the datasets. Patients were considered a match if their South African identification number was an exact match. Then, in the case of an exact match of the surname and date of births between the two datasets, we were more lenient on the edit distance for the names (also for first, second or third name matches) by allowing for a score of 500 or less.

Validation of matching
A random sample of 10% of each healthcare facility’s DR-TB patients meeting our inclusion criteria was selected. A manual matching process, considered the ‘gold standard’, was followed looking for patients in the corresponding ART register. We calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NVP).

Statistical analysis
We compared demographics, TB characteristics and outcomes between those patients we could match and those we could not. We describe completeness and discrepancies of common variables in both ART and DR-TB registers. For reporting of death outcomes and ART start dates we calculated a Kappa statistic to measure agreement between the two data sources. The severity of date discrepancies was assessed by calculating the proportion of dates differing by >1 month.

Results
Overall, 2,852 DR-TB patients met our inclusion criteria based on the DR-TB register data, and of these, 1,685 (59%) could be matched to the ART registers. An additional 253 patients from the DR-TB registers were found in the ART registers, having initiated ART, despite the DR-TB register indicating that they were not on ART (or this data was missing). This brought our total matched up to 1,938 (62%) and a total of 3,105 DR-TB patients meeting our inclusion criteria. While the rate of matching was high in Sites 1 and 2, with 76% and 80%, respectively, we could only match 59% of patients at Site 3. There were no substantial differences in age, gender, new treatment status, extra-pulmonary TB or TB outcome between those matched compared to those we couldn’t match to the ART register (Table 1), though the number of characteristics we could assess was limited.
In order to validate our matching algorithm, we randomly sampled 171 patients and compared the algorithm to our “gold standard” of manual matching. We found our algorithm to have a sensitivity of 87%, a specificity of 99%, a PPV of 98% and a NPV of 94%. The specificity was reduced by 1% and PPV by 2% due to an error in misclassification for one patient in the manual matching process.

Discrepancies between ART and DR-TB registers are presented in Table 2. Overall, 8.1% of patients had a discrepant date of birth, however the matching algorithm was more lenient on these if the name and surname were matched already; another 2.5% of patients had a date of birth missing in either register so these patients would have been matched on age, alongside gender and names. All patients in Site 1 had their HIV status recorded as HIV positive in the DR-TB register, but 6.2% and 4.5% of patients in Sites 2 and 3, respectively, had either a negative, unknown or missing HIV status in the DR-TB register, despite being initiated on ART. Overall, 8.7% of patients had no record of TB treatment (e.g. missing) in the ART register data and 2.5% of patients were recorded as not being on TB treatment (e.g. TB treatment incorrectly recorded as “No”) in the ART register record. Of the 217 patients whose TB treatment status was incorrectly recorded in the ART register, 82% had initiated ART prior to TB treatment and thus this is likely due to the records not being updated. However, of all patients who had initiated ART prior to TB treatment (61%, n = 1,187), majority (85%) had TB treatment status recorded correctly, demonstrating that most records had been updated in real time.

Majority (87%) had ART status correctly recorded in the DR-TB register. While ART start date was reported in both ART and DR-TB registers for most patients at Site 1 (81.2%), 67.8% were discrepant, and three quarters of those discrepant differed by >1 month. At Site 1, 12% of patients had a missing ART start date in the ART register, though the data indicated they initiated treatment. Most patients at Sites 2 and 3 did not have ART start date recorded in the DR-TB register (99.7% and 80.5%, respectively). Of the 280 patients at Site 3 that did have ART start date recorded in both registers, 15.4% had discrepant dates with 68.7% of ART start dates differing by >1 month. Overall there was poor agreement of the reporting of the ART start date between the ART and DR-TB registers (Kappa = 0.001). Sites 2 and 3 did not have ART regimen information recorded in the DR-TB register so we could not compare between the two datasets. At Site 1, where ART regimen was recorded in both DR-
TB and ART registers for 44.3% of patients, it was in agreement for majority of them (86.4%). However, 11.4% of patients at Site 1 did not have ART regimen recorded in the ART register.

Overall, 7.3% of patients had a death reported in the DR-TB register but not the ART register. Of these 80.9% were reported in the ART register as a lost to follow-up, 14.9% as transferred out, and 2.8% of patients had no outcome reported. While these may be explained by the timing of when the information gets recorded, a large proportion of these deaths (45.4%) were reported as deaths in the DR-TB register less than 3 months after the non-death outcome in the ART register and 36.9% had dates which occurred prior to the non-death outcome date in the ART register.

Overall, 3.5% had a death reported in the ART register but not the DR-TB register. Of these, 56.7% were reported as lost to follow-up in the DR-TB register, 16.4% had no outcome reported, and one patient was reportedly transferred out. The remaining patients had TB treatment-specific outcomes reported: 11.9% cured, 9.0% completed treatment, 3.0% still on treatment and one patient had failed TB treatment. Of the 67 patients with death reported in the ART register and not the DR-TB register, 29.9% were reported as deaths in the ART register <3 months after the non-death outcome in the DR-TB register and 34.3% had their death dates prior to the non-death outcome date in the DR-TB register. Overall agreement between reporting of death was good between the DR-TB and ART registers (Kappa = 0.60).

**Discussion**

The electronic DR-TB and ART registers, used by majority of public healthcare facilities across South Africa, are crucial for monitoring treatment programme outcomes and have improved the quality of the reporting to the South African National Department of Health (NDOH) and international organizations such as the World Health Organization. They have also allowed for data access by various research organizations. However, they do not come without their weaknesses. Our analysis has shown an underreporting of crucial indices of patient outcomes, in particular ART start dates and death outcomes. Close to 11% of patients had a death reported in the DR-TB register but not the ART register, or vice versa. Majority of the corresponding non-death outcomes were reported as lost to follow-up, thus we can assume the patient was marked as such when they failed to return to the
facility; additional follow-up is required to ensure that death does not go underreported. We also found poor quality of recording of ART information in EDRWeb. The majority of patients at the two study sites that used EDRWeb exclusively did not have ART start date recorded (99.7% and 80.5%, respectively). ART start dates and ART regimen are important to know for monitoring of the DR-TB programme, as well as monitoring drug interactions as new drugs are being introduced, for example dolutegravir for ART and bedaquiline for TB. Rates of DR-TB diagnoses in the ART programme are also underreported (as with Site 2 where just under half of patients did not have DR-TB status recorded in the ART register). Importantly, these discrepancies existed across sites and different systems, indicating this is a universal problem for any healthcare facility.

Our matching algorithm performed reasonably well in linking patients between datasets, however it is limited by the quality of the reporting of patient identifiers, and the sensitivity of the algorithm could be improved if the patient identifiers were accurately recorded in both registers. This highlights the need for a unique patient identifier within the public health system, something planned for in the National Health Insurance Policy proposed by the South African government (13).

Conclusions
The quality and completeness of the electronic DR-TB and ART registers is concerning for researchers and government who use it to monitor the outcomes of the South African TB and HIV programmes. Although South Africa’s public healthcare system is understaffed and overburdened and regular internal auditing of data may not be feasible, urgent attention is needed to address data gaps in the ART and DR-TB electronic systems.

In 2016, the NDOH implemented a TB module into Tier.Net aiming to integrate the TB and HIV data to increase reporting efficiency. The impact of this is yet to be determined, and while data integration can improve the quality of these data systems, accurate reporting is still crucial to ensure good data quality and their ability to have a meaningful impact on monitoring, policy, planning and epidemiological analysis. Furthermore, it is essential to have intensive, ongoing training of staff who capture data into electronic registers, constant emphasis on data quality, improvement of patient file management, and the transfer of information to the data capturing team.
Abbreviations
ART - antiretroviral therapy
DR-T-B - drug resistant tuberculosis
EDRWeb - Electronic Drug Register Web
ETR - electronic TB register
FIS - Focal Point Information System
HIV - human immunodeficiency virus
IQR - interquartile range
MDR - multi-drug resistant
NDOH - National Department of Health
NGOon - Governmental Organization
NVP - negative predictive value
PPV - positive predictive value
RR - rifampicin-resistant
TB - tuberculosis
TE - TherapyEdge-HIV

Ethics and consent to participate, consent for publication
Ethical approval was provided by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (M160506). The study protocol was reviewed by the Institutional Review Board of the University of Witwatersrand who approved the data collection without informed consent.

Availability of data and materials
The data is owned by the study site and National Department of Health (South Africa) and governed by the Human Research Ethics Committee (University of Witwatersrand, Johannesburg, South Africa).

All relevant data is included in the paper and supplementary tables. The full data are available from the Health Economics and Epidemiology Research Office for researchers who meet the criteria for access to confidential data and have approval from the owners of the data (information@heroza.org).
Competing interests
The authors declare that they have no competing interests.

Funding
This study has been made possible by the generous support of the American People and the President’s Emergency Plan for AIDS Relief (PEPFAR) through US Agency for International Development (USAID) under the terms of Cooperative Agreements AID–674–A–12–00029 and 72067419CA00004 to Health Economics and Epidemiology Research Office. The contents are the responsibility of the Health Economics and Epidemiology Research Office, a Division of the Wits Health Consortium (Pty) Ltd and do not necessarily reflect the views of USAID or the United States Government.

Authors’ contributions
LJ conducted the analysis and prepared the manuscript. DE, RB, SA, KW and LL contributed towards the analytical thinking and design, while DS, RB, and NI provided advice and clinical input. All authors contributed to the interpretation of data and reviewed the manuscript.

Acknowledgements
Special thanks to Dr Nalini Singh, Dr Iqbal Master, Dr Nompumelelo Mthupha, Sr Loretta van der Broeck, Ms Lebogang Ngolele and Ms Melda Musina.

References
1. UNAIDS. Country factsheet: South Africa. http://www.unaids.org/en/regionscountries/countries/southafrica: 2017.
2. WHO. Global tuberculosis report. http://www.who.int/tb/publications/global_report/en/: 2018.
3. Osler M, Hilderbrand K, Hennessey C, Arendse J, Goemaere E, Ford N, et al. A three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. J Int AIDS Soc. 2014;17:18908.
4. du Preez K, Schaaf HS, Dunbar R, Swartz A, Bissell K, Enarson DA, et al. Incomplete registration and reporting of culture-confirmed childhood tuberculosis diagnosed in hospital. Public Health Action. 2011;1(1):19–24.
5. Mlotshwa M, Smit S, Williams S, Reddy C, Medina-Marino A. Evaluating the electronic tuberculosis register surveillance system in Eden District, Western Cape, South Africa, 2015. Glob Health Action. 2017;10(1):1360560.
6. Podewils LJ, Bantubani N, Bristow C, Bronner LE, Peters A, Pym A, et al. Completeness and Reliability of the Republic of South Africa National Tuberculosis (TB) Surveillance System. BMC Public Health. 2015;15:765.

7. Rose PC, Schaaf HS, du Preez K, Seddon JA, Garcia-Prats AJ, Zimri K, et al. Completeness and accuracy of electronic recording of paediatric drug-resistant tuberculosis in Cape Town, South Africa. Public Health Action. 2013;3(3):214-9.

8. Bristow CC, Dilraj A, Margot B, Podewils LJ. Lack of patient registration in the electronic TB register for sputum smear-positive patients in KwaZulu-Natal, South Africa. Tuberculosis (Edinb). 2013;93(5):567-8.

9. Levenshtein VI. Binary codes capable of correcting deletions, insertions, and reversals. Soviet Physics Doklady. 1966;10(8):707-10.

10. SAS Institute Inc. (2018). “COMPGED Function.” Accessed September 1, 2018. http://support.sas.com/documentation/cdl/en/lrdict/64316/HTML/default/viewer.htm#a002206133.htm.

11. Cadieux R, Bretheim DR. Matching Rules: Too Loose, Too Tight, or Just Right? SAS Global Forum 2014, Washington DC, March 23-26, 2014. 2014;Paper 1674-2014.

12. Salas SB, Varga A, Shuster E. Fun with Address Matching: Use of the COMPGED Function and the SQL Procedure. SAS Global Forum 2018, April 8-11, 2018 - Denver, Colorado. 2018;Paper 2487-2018.

13. South African Department of Health National Health Insurance Policy. http://www.health.gov.za/index.php/nhi?download = 2257:white-paper-nhi–2017: 2017.

Tables

Table 1: Differences between matched and unmatched cohort of DR-TB patients initiated on antiretroviral therapy
### Table 2: Discrepancies in data found between ART and DR-TB registers in patients matched between data sources

| Site, n (%)                          | All DR-TB/ART patients (n=3,105) | Not matched to ART data (n=1,167) | Matched to ART data (n=1,938) |
|--------------------------------------|----------------------------------|-----------------------------------|--------------------------------|
| Site 1 (FIS/TE)                      | 186 (6.0%)                       | 37 (3.2%)                         | 149 (7)                        |
| Site 2 (EDRWeb/Tier.Net)             | 449 (14.5%)                      | 109 (9.4%)                        | 340 (17)                       |
| Site 3 (EDRWeb/Tier.Net)             | 2,470 (79.5%)                    | 1,021 (87.5%)                     | 1,449 (74)                     |

### Gender, n (%)                          | All DR-TB/ART patients (n=3,105) | Not matched to ART data (n=1,167) | Matched to ART data (n=1,938) |
|--------------------------------------|----------------------------------|-----------------------------------|--------------------------------|
| Female                               | 1,615 (52.1%)                    | 614 (52.7%)                       | 1,001 (52)                     |
| Male                                 | 1,489 (48.0%)                    | 553 (47.4%)                       | 936 (48)                       |

### Age, median (IQR)                    | All DR-TB/ART patients (n=3,105) | Not matched to ART data (n=1,167) | Matched to ART data (n=1,938) |
|--------------------------------------|----------------------------------|-----------------------------------|--------------------------------|
| New                                  | 35 (29-41)                       | 35 (30-41)                        | 34 (29-41)                     |

### Patient category                     | All DR-TB/ART patients (n=3,105) | Not matched to ART data (n=1,167) | Matched to ART data (n=1,938) |
|--------------------------------------|----------------------------------|-----------------------------------|--------------------------------|
| New                                  | 1,196 (38.5%)                    | 430 (36.8%)                       | 766 (39)                       |
| Treatment failure                    | 1,201 (38.7%)                    | 465 (39.8%)                       | 736 (39)                       |
| Relapse                              | 495 (15.9%)                      | 198 (17.0%)                       | 297 (15)                       |
| Treatment after loss to follow-up    | 183 (5.9%)                       | 64 (5.5%)                         | 119 (6)                        |
| Transfer-in                          | 1 (<0.1%)                        | 1 (0.1%)                          | 0 (0)                          |
| Other                                | 7 (0.2%)                         | 4 (0.3%)                          | 3 (0)                          |
| Unknown                               | 22 (0.7%)                        | 5 (0.4%)                          | 17 (1)                         |

### TB type                              | All DR-TB/ART patients (n=3,105) | Not matched to ART data (n=1,167) | Matched to ART data (n=1,938) |
|--------------------------------------|----------------------------------|-----------------------------------|--------------------------------|
| Extra-pulmonary TB                   | 82 (2.6%)                        | 21 (1.7%)                         | 61 (3)                         |
| Pulmonary TB                         | 2,672 (86.1%)                    | 1,045 (89.6%)                     | 1,627 (84)                     |
| Missing                              | 351 (11.3%)                      | 101 (8.7%)                        | 250 (13)                       |

### TB outcome                           | All DR-TB/ART patients (n=3,105) | Not matched to ART data (n=1,167) | Matched to ART data (n=1,938) |
|--------------------------------------|----------------------------------|-----------------------------------|--------------------------------|
| Cure                                  | 1,038 (33.4%)                    | 431 (36.9%)                       | 607 (31)                       |
| Completed treatment                  | 661 (21.3%)                      | 210 (18.0%)                       | 451 (23)                       |
| Death                                 | 557 (17.9%)                      | 208 (17.8%)                       | 349 (18)                       |
| Treatment failure                    | 72 (2.3%)                        | 19 (1.6%)                         | 53 (3)                         |
| Lost to follow-up                    | 689 (22.2%)                      | 276 (23.7%)                       | 413 (21)                       |
| Transferred out                      | 30 (1.0%)                        | 13 (1.1%)                         | 17 (1)                         |
| Still on treatment                   | 17 (0.5%)                        | 2 (0.2%)                          | 15 (0)                         |
| Other                                 | 1 (0.0%)                         | 0 (0.0%)                          | 1 (0)                          |
| Not specified                         | 27 (0.9%)                        | 3 (0.3%)                          | 24 (1)                         |

Abbreviations: DR-TB=drug resistant tuberculosis, ART=antiretroviral therapy, FIS=Focal Point Information System, TE=TherapyEdge-HIV™, EDRWeb=Electronic Drug Register Web, Tier.net = The Integrated Electronic Registers, IQR = interquartile range,
| Reporting of date of birth | Site 1 (FIS/TE) (n=149) | Site 2 (EDRWeb/ Tier.Net) (n=340) | Site 3 (EDRWeb/ Tier.Net) (n=1,449) |
|---------------------------|--------------------------|-----------------------------------|-------------------------------------|
| **Agree**                 | 92.6% (138)              | 92.7% (315)                       | 88.3% (1,279)                       |
| **Discrepant between DR-TB and ART register** | 7.4% (11)               | 7.4% (25)                         | 8.4% (121)                          |
| **Missing in ART register** | 0.0% (0)                | 0.0% (0)                          | 0.1% (2)                            |
| **Missing in DR-TB register** | 0.0% (0)                | 0.0% (0)                          | 3.2% (47)                           |
| **DR-TB treatment recorded in ART register** |                        |                                   |                                     |
| Not recorded/missing      | 3.4% (5)                 | 42.4% (144)                       | 1.4% (20)                           |
| Has not started TB treatment | 0.0% (0)               | 2.7% (9)                          | 2.7% (39)                           |
| **Started TB treatment**  | 96.6% (144)              | 55.0% (187)                       | 95.9% (1,390)                       |
| **HIV status reported in DR-TB register** |                        |                                   |                                     |
| Positive                  | 100% (149)               | 93.8% (319)                       | 95.6% (1,385)                       |
| Negative                  | 0.0% (0)                 | 5.6% (19)                         | 2.6% (37)                           |
| Unknown or missing        | 0.0% (0)                 | 0.6% (2)                          | 1.9% (27)                           |
| **ART status recorded in DR-TB register** |                        |                                   |                                     |
| Not recorded/missing      | 0.0% (0)                 | 1.5% (5)                          | 3.7% (53)                           |
| Has not started ART       | 6.7% (10)                | 5.6% (19)                         | 11.7% (169)                         |
| **Started ART**           | 93.3% (139)              | 92.9% (316)                       | 84.7% (1,227)                       |
| **Reporting of ART start date** |                        |                                   |                                     |
| Not recorded in either register | 1.3% (2)              | 0.0% (0)                          | 0.1% (2)                            |
| Recorded in ART register, but not DR-TB register | 6.7% (10)               | 99.7% (339)                       | 80.5% (1,167)                       |
| Recorded in DR-TB register, but not ART register | 10.7% (16)              | 0.0% (0)                          | 0.0% (0)                            |
| Recorded in both registers | 81.2% (121)             | 0.3% (1)                          | 19.3% (280)                         |
| ART start dates agree     | 32.2% (39/121)           | 0.0% (0/1)                        | 84.6% (237/280)                     |
| ART start dates differ by ≤ 1 month | 17.3% (21/121)       | 0.0% (0/1)                        | 5.4% (15/280)                       |
| ART start dates differ by > 1 month | 50.4% (61/121)       | 100% (1/1)                        | 10.0% (28/280)                      |
| **Reporting of ART regimen** |                        |                                   |                                     |
| Not recorded in either register | 8.1% (12)              | 0.0% (0)                          | 0.0% (0)                            |
| Recorded in ART register, but not DR-TB register | 44.3% (66)              | 100% (340)                        | 100% (1,449)                        |
| Recorded in DR-TB register, but not ART register | 3.4% (5)               | 0.0% (0)                          | 0.0% (0)                            |
| Recorded in both registers | 44.3% (66)              | 0.0% (0)                          | 0.0% (0)                            |
| ART regimens agree        | 86.4% (57/66)            | N/A                               | N/A                                 |
| **Reporting of death and date of death** |                        |                                   |                                     |
| No deaths in either register | 81.9% (122)            | 84.4% (287)                       | 76.8% (1,113)                       |
| Death in ART register, but not DR-TB register | 2.7% (4)               | 1.5% (5)                          | 4.0% (58)                           |
| **Reported in DR-TB register as:** |                        |                                   |                                     |
| Lost to follow-up          | 3                       | 5                                 | 30                                  |
| Transferred out            | 1                       | 0                                 | 0                                   |
| Cured                      | 0                       | 0                                 | 8                                   |
| Treatment completed        | 0                       | 0                                 | 6                                   |
| Still on treatment         | 0                       | 0                                 | 2                                   |
| Treatment failure          | 0                       | 0                                 | 1                                   |
| Not specified              | 0                       | 0                                 | 11                                  |
| Death in DR-TB register, but not ART register | 4.7% (7)               | 2.9% (10)                         | 8.6% (124)                          |
| **Reported in ART register as:** |                        |                                   |                                     |
| Lost to follow-up          | 0                       | 8                                 | 106                                 |
| Transferred out            | 3                       | 2                                 | 16                                  |
| Not specified              | 4                       | 0                                 | 0                                   |
| Death in both registers    | 10.7% (16)              | 11.2% (38)                        | 10.6% (154)                         |
| Death dates agree          | 25.0% (4/16)            | 55.3% (21/38)                     | 59.1% (91/154)                      |
| Death dates differ by ≤ 1 month | 31.3% (5/16)         | 39.5% (15/38)                     | 26.0% (40/154)                      |
| Death dates differ by > 1 month | 43.8% (7/16)          | 5.3% (2/38)                       | 14.9% (23/154)                      |
| Death reported in ART register prior to non-death outcome in DR-TB register | 0.0% (0) | 0.3% (1) | 1.5% (22) |
| Death reported in DR-TB register prior to non-death outcome in ART register | 0.0% (0) | 0.9% (3) | 3.4% (49) |
| Lost to follow-up in ART register, death recorded in DR-TB register within 3 months | 0.0% (0) | 1.8% (6) | 4.6% (66) |
| Lost to follow-up in DR-TB register, death recorded in ART register within 3 months | 2.0% (3) | 0.9% (3) | 0.5% (7) |
| Transferred out in ART register, death recorded in DR-TB register within 3 months | 0.7% (1) | 0.3% (1) | 0.4% (5) |
| Transferred out in DR-TB register, death recorded in ART register within 3 months | 0.0% (0) | 0.0% (0) | 0.0% (0) |

Abbreviations: DR-TB=drug resistant tuberculosis, ART=antiretroviral therapy, FIS=Focal Point Information System, TE=TherapyEdge-HIV™, EDRWeb=Electronic Drug Register Web, Tier.net = The
Integrated Electronic Registers